- Galapagos (NASDAQ:GLPG) announces that the first patient has been enrolled in its study to evaluate the effectiveness and safety of filgotinib in treating patients with rheumatoid arthritis (RA) in a real-world setting.
- The FILOSOPHY study is a prospective, non-interventional cohort study enrolling about 1500 patients across Europe.
- The primary objective of the study is to evaluate the treatment persistence rate at 24 months, defined as the rate of patients continuing to receive filgotinib 24 months from treatment initiation.
- Filgotinib is approved and marketed as Jyseleca (200mg and 100mg tablets) in the Europe Union, Great Britain and Japan for the treatment of certain adults with moderate to severe active RA.
- Galapagos' collaboration partner Gilead Sciences (NASDAQ:GILD) had submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat moderately to severely active ulcerative colitis (UC), last month.